Everything below concerns PPARδ. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-10-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | GW501516, GW-501516, GW 501516, endurobol | Names vary in research and anti-doping documents. |
| Chemical class | Synthetic PPARδ agonist | Small-molecule nuclear receptor ligand. |
| CAS Registry Number | 317318-70-0 | Identifier commonly associated with GW501516. |
| Appearance | White to off-white powder | Typical for purified research material. |
| Solubility | Low in water; soluble in DMSO and ethanol | Organic solvents are common for laboratory stock solutions. |
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
== Structure == LCRs were originally thought to be unstructured and flexible linkers that served to separate the structured (and functional) domains of complex proteins, but they are also capable of forming secondary structures, like helices (more often) and even sheets. They may play a structural role in proteins such as collagens, myosin, keratins, silk, cell wall proteins. Tandem repeats of short oligopeptides that are rich in glycine, proline, serine or threonine are capable of forming flexible structures that bind ligands under certain pH and temperature conditions. Proline is a well-known alpha-helix breaker, however, amino acid repeats composed of proline may form poly-proline helices.
=== Military Union and People's Alliance === The dismissal of Kimon Georgiev was followed by the purge of other key figures of the Union by the end of 1920. Despite the government's measures, the Military Union was gradually restored with the active efforts of Nikola Rachev, Damyan Velchev and Kimon Georgiev - the structure of the organization in the army was reorganized, with fewer people involved in its activities, but under a tighter conspiracy. His political career started in 1921, where he was one of the founders of the organization People's Alliance and kept ties with the Military Union. He also participated in the negotiation ties between opposition parties to create the Constitutional Bloc in 1922.
== Victims == Fred and Rose West are known to have committed at least twelve murders between 1967 and 1987. Many investigators, authors and journalists who have studied the case believe there are other victims whose bodies have never been found. Prior to his suicide, police had amassed more than 108 hours of tape-recorded interviews with Fred, from both the period when he claimed to have acted alone in the commission of the murders and after he began to portray Rose as being the more culpable participant. On several occasions, Fred made cryptic hints he had murdered several other girls but refused to divulge any further information. Fred claimed to Janet Leach that there were up to 20 further victims he and Rose had murdered, "not in one place but spread around," and that he intended to reveal the location of one body per year to investigators. The following are murder victims attributed or partly attributed to Rose West:
2024 Dissolution Honours: Nominations for peerages include Theresa May (former prime minister), Chris Grayling (former justice secretary), Sir Graham Brady (chair of the 1922 Committee), Craig Mackinlay (Conservative MP), Harriet Harman (former deputy leader of the Labour Party), Margaret Beckett (former foreign secretary), Margaret Hodge (former Labour MP), and Dr Hilary Cass (chair of the Cass Review). 5 July Results of the 2024 United Kingdom general election: Sir Keir Starmer becomes the new prime minister of the United Kingdom, following a landslide victory for Labour in the general election. The Conservatives are reduced to just 121 seats, the lowest number of MPs in their 190-year history. Among the high-profile losses are former prime minister Liz Truss, former cabinet minister Sir Jacob Rees-Mogg, Commons leader Penny Mordaunt, and Defence Secretary Grant Shapps. The Liberal Democrats, led by Sir Ed Davey, achieve their best ever result with 71 seats. The Green Party achieve their best ever result, quadrupling their number of seats to four. Reform UK gain their first seats in Parliament, which includes party leader Nigel Farage taking the constituency of Clacton. The SNP suffers heavy losses, going from 48 seats to just nine. Sinn Féin wins seven seats, making it the largest party across Northern Ireland. Starmer ministry: Starmer appoints his first cabinet. This includes Angela Rayner as Deputy Prime Minister and Rachel Reeves as Chancellor of the Exchequer, making her the first woman to hold the office.
Spent nuclear fuel from normal light water reactors contains plutonium, but it is a mixture of plutonium-242, 240, 239 and 238. The mixture is not sufficiently enriched for efficient nuclear weapons, but can be used once as MOX fuel. Accidental neutron capture causes the amount of plutonium-242 and 240 to grow each time the plutonium is irradiated in a reactor with low-speed "thermal" neutrons, so that after the second cycle, the plutonium can only be consumed by fast neutron reactors. If fast neutron reactors are not available (the normal case), excess plutonium is usually discarded, and forms one of the longest-lived components of nuclear waste. The desire to consume this plutonium and other transuranic fuels and reduce the radiotoxicity of the waste is the usual reason nuclear engineers give to make fast neutron reactors. The most common chemical process, PUREX (Plutonium–URanium EXtraction), reprocesses spent nuclear fuel to extract plutonium and uranium which can be used to form a mixed oxide (MOX) fuel for reuse in nuclear reactors. Weapons-grade plutonium can be added to the fuel mix. MOX fuel is used in light water reactors and consists of 60 kg of plutonium per tonne of fuel; after four years, three-quarters of the plutonium is burned (turned into other elements). MOX fuel has been in use since the 1980s, and is widely used in Europe. Breeder reactors are specifically designed to create more fissionable material than they consume. MOX fuel improves total burnup.
Sources: en.wikipedia.org
== Earliest roots == Between around 3000 and 1200 BCE, the Ancient Egyptians and Mesopotamians made contributions to astronomy, mathematics, and medicine, which later entered and shaped Greek natural philosophy of classical antiquity, a period that profoundly influenced the development of what came to be known as biology.
=== Ontologies and data integration === Biological ontologies are directed acyclic graphs of controlled vocabularies. They create categories for biological concepts and descriptions so they can be easily analyzed with computers. When categorised in this way, it is possible to gain added value from holistic and integrated analysis. The OBO Foundry was an effort to standardise certain ontologies. One of the most widespread is the Gene ontology which describes gene function. There are also ontologies which describe phenotypes.
The Wallerian degeneration pathway has been further illuminated by the discovery that sterile alpha and TIR motif containing 1 (SARM1) protein plays a central role in the Wallerian degeneration pathway. The gene was first identified in a Drosophila melanogaster mutagenesis screen, and subsequently knockouts of its homologue in mice showed robust protection of transected axons comparable to that of WldS. SARM1 catalyzes the synthesis and hydrolysis of cyclic ADP-ribose (cADPR) from NAD+ to ADP-ribose. SARM1 activation locally triggers a rapid collapse of NAD+ levels in the distal section of the injured axon, which then undergoes degeneration. This collapse in NAD+ levels was later shown to be due to SARM1's TIR domain having intrinsic NAD+ cleavage activity. The SARM1 protein has four domains, a mitochondrial localization signal, an auto-inhibitory N-terminus region consisting of armadillo/HEAT motifs, two sterile alpha motifs responsible for multimerization, and a C-terminus Toll/Interleukin-1 receptor that possesses enzymatic activity. Activation of SARM1 is sufficient to collapse NAD+ levels and initiate the Wallerian degeneration pathway. The activity of SARM1 helps to explain the protective nature of the survival factor NMNAT2, as NMNAT enzymes have been shown to prevent SARM1-mediated depletion of NAD+. This relationship is further supported by the fact that mice lacking NMNAT2, which are normally not viable, are completely rescued by SARM1 deletion, placing NMNAT2 activity upstream of SARM1.
variegation Variation or irregularity in a particular phenotype, especially a conspicuous visible trait such as color or pigmentation, occurring simultaneously in different parts of the same individual organism due to any of a variety of causes, such as X-inactivation, mitotic recombination, transposable element activity, position effects, or infection by pathogens.
Sources: en.wikipedia.org
=== Losses === The bank's deposits increased from $62 billion in March 2020 to $124 billion in March 2021, benefiting from the impact of the COVID-19 pandemic on science and technology. Most of these deposits were invested in long-term Treasury bonds as the bank sought a higher return on investment than was available on shorter-term bonds. These long-term bonds fell in current market value as interest rates rose during the 2021–2023 inflation surge and they became less attractive as investments relative to newer bond issues. In April 2022, SVB's chief risk officer stepped down, and a successor was not named until January 2023—a period coinciding with the period of interest rate increases. At the end of 2022, the bank had a $117 billion bond portfolio, divided into a $91.3 billion held-to-maturity portfolio (meaning it was not marked to market and profits or losses would not be realized until maturity) and a $26 billion available-for-sale portfolio (which as the name implies was marked to market). At that point in time, its marked-to-market unrealized losses for securities held to maturity exceeded $15 billion. The bank did not hedge against interest rate risk on that part of its bond portfolio, apparently for the same reason that most banks do not: the hedge itself would bounce around with the market, while the point of holding bonds to maturity is to hold them at par. Most banks minimize interest rate risk in their held-to-maturity portfolios by buying shorter-term bonds.
=== Post‑marketing surveillance and safety signals === Following the launch of the once‑monthly paliperidone palmitate formulation (Xeplion) in Japan on 19 November 2013, the Early Post‑Marketing Phase Vigilance (EPPV) system detected a signal of increased mortality: 32 deaths were reported among an estimated 11,000 patients during the six‑month EPPV period. The most common causes of death were sudden cardiac death (12 confirmed and 4 suspected cases), suicide (7 cases), and neuroleptic malignant syndrome (4 cases). Of the 32 deaths, 59.4% were in patients over 50 years of age, 71.9% had cardiovascular risk factors, and 78.1% were receiving antipsychotic polypharmacy. Earlier in the EPPV period, in April 2014, it had been reported that 21 Japanese people who had received shots of the long-acting injectable paliperidone palmitate had died, out of 10,700 individuals prescribed the drug. An observational study of the French pharmacovigilance database identified 13 deaths and 14 life‑threatening events among 473 paliperidone palmitate-related adverse drug reaction reports between 1 January 2013 and 31 December 2019. The reactions were primarily cardiorespiratory, with cardiac arrests and sudden unexpected deaths often occurring 10–14 days after a once‑monthly injection (or 11–24 days after a three‑monthly injection), consistent with peak plasma drug levels, leading the authors to hypothesize that supratherapeutic drug levels may underlie these events. A 2025 real‑world pharmacovigilance study using the U.S.
In March 2001 the license for Trovan was withdrawn in Europe, by the European Commission due to liver toxicity and some deaths. In June 2010, the US Supreme Court rejected Pfizer's appeal against a ruling allowing lawsuits by the Nigerian families to proceed. In December 2010, the United States diplomatic cables leak indicated that Pfizer hired investigators to find evidence of corruption against Nigerian attorney general Michael Aondoakaa to persuade him to drop legal action. The Washington Post reporter Joe Stephens, who helped break the story in 2000, called these actions "dangerously close to blackmail". In response, the company released a press statement describing the allegations as "preposterous" and saying that it acted in good faith. Aondoakka, who had allegedly demanded bribes from Pfizer in return for a settlement of the case, was declared unfit for office and had his U.S. visa revoked in association with corruption charges in 2010. The lawsuits were eventually settled out of court. Pfizer committed to paying US$35 million "to compensate the families of children in the study", another $30 million to "support healthcare initiatives in Kano", and $10 million to cover legal costs. Payouts began in 2011.
Sources: en.wikipedia.org
Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.
No. Cardarine is not a steroid hormone; it targets the nuclear receptor PPARδ. Its classification in anti-doping rules differs from anabolic steroids, though it remains prohibited in sport.
Early rodent studies reported tumor formation at multiple sites, which raised safety concerns. Sponsors stopped clinical development, and no approved human product exists.
Cardarine is a common name for GW501516, a synthetic PPARδ agonist developed for research. It has not been approved as a medication in any country. It is classified as an unapproved drug and a prohibited substance in sport.